# PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

> **NCT05357846** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 422 (estimated)

## Conditions studied

- Squamous Cell Esophageal Carcinoma
- Esophageal Cancer
- Oesophageal Cancer

## Interventions

- **DRUG:** Sintilimab
- **RADIATION:** Preoperative radiotherapy
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **PROCEDURE:** esophagectomy

## Key facts

- **NCT ID:** NCT05357846
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2031-01-01
- **Final completion:** 2031-01-31
- **Target enrollment:** 422 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357846, "PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05357846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*